Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOV-002 + carboplatin
- Development stage
- Phase 2
- Lead developer
- Cellectar Biosciences
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
NOV-002 + carboplatin is a combination therapy comprising **NOV-002**, a mimetic of oxidized glutathione (GSSG), and **carboplatin**, a DNA crosslinking platinum-based chemotherapeutic. NOV-002 modulates cellular redox balance through S-glutathionylation of proteins, impacting signaling pathways including AKT, JAK2, and STAT5, and acts as an immunostimulant and myeloproliferative agent. Carboplatin exerts cytotoxicity by DNA crosslinking and interfering with cell division. As a combination, this regimen was investigated for enhanced efficacy and tolerance of chemotherapy, particularly in advanced non–small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer. NOV-002 does not directly add to carboplatin's cytotoxicity but aims to improve hematologic recovery and reduce chemotherapy toxicity via redox modulation[1][2][3][4][5].
- Other names
- glutathione disulfide mimetic + carboplatin
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)DNAERKJAK2 (Janus kinase 2)JNK (Mitogen-activated protein kinase kinase kinase family)STAT5A (STAT5)Actin filament proteinsCSPT (Cell-surface protein thiol)GSR (Glutathione reductase)RK (Ribokinase)P4HB (Protein disulfide-isomerase)
Beyond the preview
Go deeper on NOV-002 + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOV-002 + carboplatin.